IMAGING TUMOR METABOLISM IN GBM PATIENTS TO HELP OPTIMIZE ANTI-TUMOR THERAPIES. THE ABILITY TO MONITOR PKM2, A KEY REGULATOR OF GBM METABOLISM, ALLOWS POTENTIAL MONITORING ESSENTIAL TO EARLY THERAPY RESPONSE.

PI: Sanjiv Sam Gambhir M.D., Ph.D.
Chair, Department of Radiology
Director, Molecular Imaging Program at Stanford
Director, Canary Center at Stanford for Cancer Early Detection
Stanford University School of Medicine

Close Menu